Citi Starts Sarepta Therapeutics (SRPT) at Buy, 'Optimistic Outlook as DMD Gene Therapy Goes in Front of FDA Again'
Tweet Send to a Friend
(Updated - December 12, 2023 4:10 PM EST)
Citi analyst David Hoang initiates coverage on Sarepta Therapeutics (NASDAQ: SRPT) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Citi analyst David Hoang initiates coverage on Sarepta Therapeutics (NASDAQ: SRPT) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
